Background. The expected value of sample information (EVSI) determines the economic value of any future study with a specific design aimed at reducing uncertainty about the parameters underlying a health economic model. This has potential as a tool for trial design; the cost and value of different designs could be compared to find the trial with the greatest net benefit. However, despite recent developments, EVSI analysis can be slow, especially when optimizing over a large number of different designs. Methods. This article develops a method to reduce the computation time required to calculate the EVSI across different sample sizes. Our method extends the moment-matching approach to EVSI estimation to optimize over different sample sizes for the underlying trial while retaining a similar computational cost to a single EVSI estimate. This extension calculates the posterior variance of the net monetary benefit across alternative sample sizes and then uses Bayesian nonlinear regression to estimate the EVSI across these sample sizes. Results. A health economic model developed to assess the cost-effectiveness of interventions for chronic pain demonstrates that this EVSI calculation method is fast and accurate for realistic models. This example also highlights how different trial designs can be compared using the EVSI. Conclusion. The proposed estimation method is fast and accurate when calculating the EVSI across different sample sizes. This will allow researchers to realize the potential of using the EVSI to determine an economically optimal trial design for reducing uncertainty in health economic models. Limitations. Our method involves rerunning the health economic model, which can be more computationally expensive than some recent alternatives, especially in complex models.
The expected value of sample information (EVSI) 1 quantifies the expected economic benefit of a data collection exercise with a given design. In general, in the context of health economic decision making, new data update information about the parameters underlying a health economic model, which then updates information about the optimal treatment or intervention. This reduces the possibility of funding an inefficient treatment, which may have been deemed economically efficient because of deficiencies in the current information.
The EVSI is a value of information (VoI) measure 2 used to analyze the potential benefit of resolving
The Hospital for Sick Children, Toronto, Canada and University of Toronto, Canada (AH). Department of Statistical Science, University College London, London, UK (IM, GB). The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Financial support for this study was provided in part by grants from the Engineering and Physical Sciences Research Council and the Canadian Institutes for Health Research through the PERC SPOR iPCT grant (AH) and Mapi (GB). The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.
uncertainty in a decision model. Among these measures, the EVSI has the greatest potential to inform research decisions as it quantifies the economic benefit of a specific study. This value can be compared directly with the cost of the trial to determine whether a study should go ahead, making the EVSI an important tool for decision makers and funders looking to efficiently allocate research and development resources. 3 In addition to this, the EVSI has potential as a tool for trial design when it is calculated for a number of different designs. 4 The trial with the largest ''net'' economic value is then selected, by considering the cost of implementation alongside the EVSI. Using the EVSI in this setting ensures that the data collected in the study are sufficient to reliably inform the health economic model. This implies that, following the study, the costeffectiveness of the different treatments can be assessed based on a robust evidence base, which is a key requirement within publicly funded health systems in which treatments/interventions must demonstrate costeffectiveness over competitors. [5] [6] [7] [8] However, the computational time required to calculate the EVSI based on realistic health economic models has largely restricted its practical application. 9 With the exception of cases in which the health economic model conforms to certain conditions, [10] [11] [12] traditionally, the EVSI has been estimated using computationally intensive nested Monte Carlo simulations. 13 Recent methodological advances have allowed for EVSI calculations without resorting to nested simulations. [14] [15] [16] [17] [18] However, in avoiding computationally intensive simulations, these methods require either additional statistical techniques, for example, the specification of sufficient statistics 14 or the prior effective sample size, 16, 17 or additional inputs, such as a large number of likelihood calculations 15 or the weights of the posterior at different parameter inputs. 18 This can act as a barrier to implementation, with a number of recent practical EVSI calculations being carried out using nested Monte Carlo simulations. [19] [20] [21] [22] In this article, we focus on extending the momentmatching estimation method for the EVSI. 23, 24 This method significantly reduces the computational burden of the nested simulation method by rescaling the standard output from a probabilistic economic model to estimate the computationally expensive aspect of practical EVSI calculations. This rescale factor is estimated using nested simulation by rerunning the economic model for a small number of potential data sets that could arise from the proposed study and then calculating the variance of the incremental net benefit. 24 The advantage of developing a nested simulation method is that the EVSI is typically understood in terms of this simulation procedure, 3, 25 making the EVSI computation method easier to comprehend. Nested simulation methods also place no restrictions on the complexity of the underlying health economic model or the structure of the data to be collected and allow researchers to consider common trial issues such as missingness or loss to drop out in the data.
The drawback of this method is the increase in computational time compared with other EVSI calculation methods, especially in computationally intensive models, as they must be rerun. However, the extension presented in this article increases the applicability of the momentmatching method by allowing researchers to estimate the EVSI across different sample sizes for the future study while maintaining the same number of nested simulations required for a single EVSI estimate. Specifically, we use Bayesian nonlinear regression to estimate the functional form of the decreasing relationship between the variance of the incremental net benefit and the sample size of proposed study. This method requires a single additional model run per sample size, thereby allowing the EVSI to be used as a tool for sample size optimization. One advantage of using Bayesian regression is that the uncertainty in the EVSI that arises from its estimation using simulation can easily be modeled. In addition to this, the structure of EVSI gives information about the functional relationship between the variance of the incremental net benefit and the sample size, which can then be used to define priors in the Bayesian regression. Finally, EVSI is an inherently Bayesian procedure, and therefore, our calculation method fits within this wider framework.
To present this extension, we formally introduce the EVSI in the next section and the standard momentmatching method. 26 We then present a Bayesian nonlinear model that can be used to estimate the EVSI across different sample sizes based on 1 simulation per sample size. Finally, we implement this method using a real-life health economic model developed to compare treatments for chronic pain. 27 We demonstrate the accuracy and computational savings of this new method by comparing our estimates with the full nested Monte Carlo simulation method. We also highlight how the EVSI could be used as a tool for trial design by considering two alternative designs across a range of sample sizes.
The EVSI
The EVSI quantifies the economic benefit of using a specific method for data collection to reduce the uncertainty about the parameters underlying a health economic model. Therefore, we begin by defining a health economic model to compare treatments for a specific disease/health state. This is characterized in terms of a vector of parameters u, used to describe the properties of the underlying disease, for example, survival probabilities, quality-of-life measures, and health service costs. In a Bayesian setting, a joint probability distribution p(u) defines the current uncertainty in these parameters and is typically informed by a number of different data sources, such as clinical trials augmented by additional information from the literature, and is required to perform probabilistic sensitivity analysis (PSA), 28 a required element of reimbursement decisions in a number of jurisdictions. [5] [6] [7] [8] In a health economic model, the value of each treatment is normally defined using a ''net benefit'' function dependent on the model parameters, NB u t for t = 1, . . . , T possible interventions/alternatives. The probability distribution p(u) then induces a distribution for the net benefit for each treatment. Typically, NB u t is calculated by averaging over the individual-level response to treatments, implying that if the parameters were known exactly, then NB u t for t = 1, . . . , T would also be known. The optimal treatment given current evidence is then found by averaging over all uncertainty for each treatment, N B t = E u NB u t Â Ã , and then finding the treatment with the highest expected net benefit given current uncertainty, arg max t N B t .
However, this method could select a nonoptimal treatment because of the potential deficiencies in our current information about the model parameters. Additional information gleaned from a study would update the distribution of the model parameters, which would then update the distribution of the net benefit. This could change the optimal treatment, indicating that the collected information has value to a decision maker as the additional data have prevented patients from receiving an inefficient treatment and financial resources are saved.
Formally, a study collects data, denoted X, which update the information about the model parameters u. This updating falls within the Bayesian paradigm in which we consider p(u) as the prior distribution for the model parameters. The sampling distribution for the data is combined with the prior to determine a posterior for model parameters p(ujX). The net benefit for each treatment is then calculated as a function of u and the optimal treatment found by maximizing the posterior expected net benefit. The economic value of the study is then the difference between the expected net benefit of the optimal treatment with the updated information and the current information.
However, as the EVSI is calculated before the data have been collected, the study outcome is unknown. Therefore, we consider a distribution for all the possible data sets that could arise from the study and calculate the value of every study outcome. The EVSI is the average study value over all possible future data sets. Mathematically, this is expressed as
where the distribution of X can be defined through p(X, u) = p(u)p(Xju): In this setting, a good choice for the sampling distribution of the data is the likelihood we would assume for the data in the trial, if it had been run. This would align the EVSI calculation with the data analysis if the trial were run. It is usually impossible to calculate the EVSI analytically, so in practical scenarios, it is estimated using simulations. Computationally, the challenge is to compute the inner ''posterior'' expectation for the net benefit of each treatment for each possible study, E ujX NB u t Â Ã for t = 1, . . . , T . If this posterior expectation is available in closed form, then estimating the EVSI by simulation requires little computational effort, as we simply require a large number of simulated study outcomes. However, in practical models, this analytic expectation will rarely be available, so alternative methods must be used. The most general method is to estimate the inner expectation using simulations from the posterior of ujX, for a large number of different potential study outcomes. This means that the simulations required to estimate the posterior expectation are nested within the simulations of possible study outcomes, leading to a nested Monte Carlo simulation method with relatively high computational cost, as typically about 1000 simulated study outcomes are used.
Our moment-matching method reduces the number of simulated study outcomes required to estimate the EVSI to between 30 and 50 by estimating the posterior expectation of the net benefit by rescaling output from the PSA. 23 The Moment-Matching Method Thus far, we have presented the EVSI for health economic models that compare T treatments. However, for simplicity, we restrict ourselves to the dual-decision setting (i.e., t = 1, 2), before returning to the general setting in the supplementary material. To simplify the calculations still further, we work directly with the incremental net benefit (i.e., INB
. The incremental net benefit contains all the information required to make a decision between treatment 1 and treatment 2. Specifically, treatment 1 is optimal if the expected incremental net benefit is positive and treatment 2 is optimal otherwise. Therefore, to calculate the EVSI, we must estimate the posterior expectation of INB u across the different study outcomes, which we denote m X = E ujX INB u Â Ã . To further clarify the moment-matching method, a full list of notations is given in Table 1 .
Estimating the Distribution of m X Using Moment Matching
Formally, the moment-matching method is concerned with estimating the distribution of m X , denoted p(m X ). To present this method, first assume that the future sample X directly updates a subset of the model parameters f u; for example, a clinical trial would inform the primary clinical outcome but is unlikely to give information on the societal costs of the disease. It can then be shown that the distribution of m X has the same mean as the distribution of
while the variance of m X is smaller than the variance of INB f . 23 Intuitively, this behavior can be explained by noting that the larger the sample size of the hypothetical data X, the more potential values the data can take. This means that m X can deviate further from the current mean of the INB. As INB f can be considered as the limit distribution for m X as the underlying sample size tends to infinity, the variance of m X increases to the variance of INB f at the limit. Furthermore, m X is similar to INB f in terms of tail behavior and skewness for a finite sample size. 23 demonstrated that approximating p(m X ) in this manner is sufficiently accurate for EVSI estimation provided the sample size of the proposed study is sufficiently large and s 2 X is estimated accurately using the procedure outlines below. In general, the moment-matching method requires the estimation of INB f and s 2 X to calculate the EVSI.
can be estimated by rescaling the realizations The variance of m X (N ) for potential data sets of a given sample size N Q
The number of nested simulations taken to estimate the EVSI using moment matching f q
The q th row of a matrix that contains the quantiles of the realizations for f for q = 1, . . . , Q N q
The q th element in a vector of sample sizes between the minimum and maximum sample sizes for q = 1, . . . , Q X q
The q th simulated potential data set for q = 1, . . . , Q; data sets are simulated conditional on f q only in the standard method and on the pair (f q , N q ) in the extension s
The posterior variance of the incremental net benefit conditional on the data set
The simulated values of INB f that have been rescaled to approximate simulations from the distribution of m X ; the subscript s defines the s th simulated value for s = 1, . . . , S s The residual variance for Bayesian nonlinear regression used to estimate s 
Estimating Simulated Values of IN B f
The first element of the moment-matching method is to estimate simulated values of INB f , denoted INB f s for s = 1, . . . , S. These can be found in a computationally efficient manner using methods developed for the calculation of the expected value of partial perfect information (EVPPI), which is based on the expectation in equation (2) . The main reason for using these methods is that the EVPPI is an upper bound for the EVSI and is much simpler to compute. As the EVSI must be large to indicate that a study is worthwhile, a study with a small EVPPI, the upper limit of the value, will not be economically viable, irrespective of design. Therefore, the EVPPI should always be calculated before the EVSI as a screening procedure, 29 implying that INB f s should be available before attempting to calculate the EVSI.
In most health economic models, an EVPPI calculation method based on nonparametric regression is fast and accurate. 26, 30 Estimating the Variance of m
X
The variance of m X , denoted s 2 X , is estimated using the law of total variance:
This implies that s 2 X is estimated as the difference between the variance of INB u , denoted s 2 , and the expected posterior variance of the incremental net benefit. As s 2 is estimated as the sample variance of the realization simulations of INB u , we simply require an estimate of the expected posterior variance of the incremental net benefit, where the expectation is taken across the different potential data sets.
This expected posterior variance for INB u can be accurately estimated using a small number Q of nested simulations, with 30\Q\50, provided the nested samples are undertaken using a specific method, 23 demonstrated pictorially in Figure 1 . To estimate the expected posterior variance for INB u , we begin with the results of a standard PSA procedure, represented in the left-hand panel in Figure 1 with S = 1000. In this procedure, the parameters u are simulated randomly from p(u) to give a PSA matrix with 1 column for each element of the u vector, u p for p = 1, . . . , P. Each row of this matrix is then used to calculate 1 value for the INB u , giving a distribution for the INB u . To proceed, we extract any columns of the PSA matrix that contain simulations for the parameters directly informed by the study, f. In Figure 1 , f contains 3 parameters and we, therefore, select 3 columns from among P alternatives. We then order each of these columns separately. Clearly, this will break any correlation structure between the elements of f and the relationship with INB u . Finally, from these independently ordered columns of the PSA matrix, we select Q equally spaced values to find the sample quantiles separately for each element of f. We then simulate 1 future sample for each row of sample quantiles, f q , q = 1, . . . , Q, which we denote X q . This process of simulating potential samples X q is represented in the right-hand graphic. In some settings, this method may result in simulating future samples based on parameter configurations that are unlikely given our current information, but this method has been found to accurately estimate s 2 X in practical examples. 24 Once these future samples have been generated, the posterior variance of the INB u is estimated by rerunning the health economic model based on the posterior distribution of the parameters. Specifically, the posterior for the model parameters p(ujX q ) is found by simulation for each X q , q = 1, . . . , Q. The simulated parameter values from p(ujX q ) are then used to calculate INB u in the same manner as in the original PSA analysis. We then calculate the variance of the posterior distribution of the incremental net benefit, denoted s 2 q , for each sample X q , q = 1, . . . , Q. Finally, the variance s 
Linear 
Calculating the EVSI for Different Sample Sizes
To estimate the EVSI across different sample sizes, consider that financial or clinical constraints impose practical limits on the possible sample size for the future trial. Therefore, we are attempting to estimate the EVSI on a grid of R sample sizes between these limits,
The standard Figure 1 Pictorial representation of the simulation method used to generate potential future samples X q for q = 1, . . . , Q. The left-hand panel represents a standard probabilistic sensitivity analysis procedure; darker lines represent large values for u p , p = 1, . . . , 3, while lighter lines represent smaller values. In the left-hand panel, therefore, the parameters are simulated randomly and used to calculate the incremental net benefit, which is represented as the right-hand column of this panel. In the middle panel, we select the parameters directly informed by the study (denoted f i for i = 1, . . . , 3 in this example). These parameters under investigation are reordered separately, smallest to largest, breaking any potential correlation structure. In this middle panel, the other parameters are represented using faded columns as they are not of interest. In some settings, all parameters will be under investigation, and thus no columns will be discarded. Finally, the right-hand panel selects the quantiles for each element in f separately and creates a new quantile matrix, in which each row contains the q th quantiles for all the elements in f. The future samples are generated conditional on each row in this quantile matrix using p(X j f).
moment-matching method would require R 3 Q posterior updates and model runs to estimate the EVSI on this grid, quickly becoming infeasible as R increases. Therefore, this section extends the moment-matching method, allowing us to estimate the EVSI across different sample sizes by setting R = Q and requiring only 1 posterior update per sample size. This maintains the same number of simulations between the standard method and this evaluation across sample sizes. For this extension, each potential data set X q is simulated conditional on the vector (f q , N q ), rather than solely on (f q ), represented pictorially in Figure 2 . Once these data sets X 1 , . . . , X Q , with different sample sizes, have been simulated, the extended moment-matching method proceeds as follows: each data set updates the distribution of the model parameters, and the health economic model is then run to find the posterior for the incremental net benefit conditional on this updated distribution for the parameters. The posterior variance of the incremental net benefit is then calculated, giving s 2 q for q = 1, . . . , Q.
However, to then estimate the EVSI across sample sizes, this extension requires an alternative strategy to estimate s q are generated conditional on a specific future data set X q , of size N q . This data set represents one possible future, which is subject to variation due to random sampling and dependence on the specific value of f q . In the standard moment-matching method, we take the mean of s 2 q to remove this dependence on the specific f q value. However, in this extended setting, we use regression across the different sample sizes N q to calculate the expected variance across all values of f. Therefore, we Figure 2 Pictorial representation of the sampling procedure for the future samples in the extended moment-matching method. As in Figure 1 , darker lines represent higher values for the parameters. Here, the parameters of interest f 1 to f 3 have been reordered independently and are then used to generate random samples X q for increasing sample sizes as q increases. These sample sizes are equally spaced on the square root scale.
use the values of s 2 q , obtained by simulation, to estimate the function f (N) as
where e q is an error term that captures variation in s 2 q due to using simulated data sets with sample size N q .
A Bayesian Nonlinear Model
To estimate s 2 X (N ), we define a Bayesian nonlinear model that allows us to encode our knowledge about the underlying behavior of s 2 X (N). It also allows us to propagate uncertainty from our estimation procedure into the EVSI estimate so researchers can assess the accuracy of the moment-matching procedure.
Our model is defined by assuming a functional form for the regression function,
where s To define a Bayesian model, priors must be set for h, the regression parameter, and s 2 e , the residual variance. In our analysis, a noncentral t-distribution prior (truncated at 0) was specified for the residual standard deviation s e , as suggested by Gelman. 34 In our examples, the hyperparameters for this prior were defined using observed values for s 2 q . This is because the magnitude of s 2 q changes drastically, and we wanted to generalize our method by setting default priors. Therefore, we set the prior mean for the noncentral t-distribution as the sample standard deviation of s 2 q divided by 2 and the prior variance to the sample standard deviation of s 2 q . We specified a truncated normal prior for h with a mean equal to N max 2 and variance equal to 200 3 N max . These specifications give weakly informative priors for h and s 2 e . In practice, we found that the results presented in this article were quite robust to the choice of parameters for the priors, while the distributional assumptions for the prior s 2 e had a relatively large impact on the results. Note that similar results can be obtained using ordinary least-squares regression with the same functional form given in equation (5), but it is more challenging to determine prediction intervals, and problems with convergence can also be encountered when estimating h. In addition to this, Bayesian regression fits more naturally with the framework in which EVSI calculations are undertaken.
Calculating the EVSI for Different Sample Sizes
To calculate the EVSI, we fit this nonlinear model using the estimated posterior variances from the health economic model s f s (equation [3] ) and estimate the EVSI using equation (4) .
However, as EVSI calculations require at least S computations to find the maximum between 0 and h X s for each s = 1, . . . , S, calculating the EVSI for each posterior simulation of h for each sample size considered can become computationally intensive with a large PSA simulation size S. Therefore, we wish to calculate the EVSI for only a small number posterior samples of s 2 X (N ). We advise summarizing the posterior of s 2 X (N ) by finding credible intervals for a small number of credible levels before calculating the EVSI. For example, in the first section of this article, the median and the 75% and 95% credible intervals were found to summarize the posterior of s 
Practical Considerations
The first practical consideration is that the function f (N ) changes quickly for small sample sizes, meaning that smaller values of N sizes give more information about h. Therefore, we suggest that more future samples X q are generated for small sample sizes. Practically, we achieve this by choosing N q values that are evenly spaced on the square root scale between N min and N max , although other methods are available. This has a computational advantage as Bayesian updating typically requires more computing time to estimate the posterior distribution conditional on larger data sets. Therefore, choosing N q in this manner improves fit and reduces computation time.
Next, this nonlinear regression method requires that f q and N q are uncorrelated. This is because the magnitude of s 2 q , the posterior variance of the incremental net benefit, is influenced by both f q and N q through the simulated data set X q . If f q and N q are correlated, then any regression between s Thus far, as can be seen in the right-hand side of Figure 1 , f q is increasing as q increases for each column of f. In the first section, we defined N q as increasing values between N min and N max . In this sense, all columns of f q and N q are increasing as q = 1, . . . , Q is increasing, inducing a correlation between each column of f q and N q , which biases the EVSI estimates. To avoid this bias, it is suggested that each column in the f q , q = 1, . . . , Q, is randomly reordered separately before generating X q . Figure 2 demonstrates this process pictorially, and the quantiles that were displayed in the right-hand side of Figure 1 are randomly permuted independently for each column of the f q , q = 1, . . . , Q matrix. This creates a new matrix in which each row is then combined with a sample size N q , spaced on the square root scale, to generate a potential future sample X q . Empirically, this method has been successful for estimating the variance of m X accurately even with correlated parameters, but a more sophisticated sampling strategy may be needed if the parameters are highly correlated.
Finally, as this EVSI estimation method is based on regression, its accuracy can be checked using standard model-checking procedures such as residual or qq-plots. Specifically, the residuals should exhibit no clear unmodeled structure, as in standard regression modeling.
Implementation of the Extended MomentMatching Method
This section implements our extended moment-matching method to calculate the EVSI across different sample sizes. The supplementary material demonstrates that our method is in line with other EVSI calculation methods 14,15 using a hypothetical health economic model developed by Brennan and Kharroubi. 18 In the following section, we use a practical health-economic model that evaluates different treatments for chronic pain 27 to illustrate a potential EVSI analysis that could be undertaken using the extended moment-matching method. In this analysis, we compare our method with the nested Monte Carlo simulation method to demonstrate accuracy and compare computation time.
A Health Economic Model for Chronic Pain
Sullivan et al. 27 developed a cost-effectiveness model for evaluating treatment options for chronic pain. The model is based on a Markov structure with 10 states, in which each state has an associated utility score and cost. The disease progression for chronic pain is as follows: the treatment is administered, and a patient can either experience adverse effects (AEs) of the treatment or not. The patient can then withdraw from treatment, either due to the AEs or otherwise. They can then continue to another treatment option or withdraw completely from treatment. After the second line of treatment, they either have subsequent treatment or discontinue (these are absorbing states).
In the standard model, a patient can either be offered morphine or a innovative treatment in the first line of treatment. If they withdraw and receive a second treatment, they are offered oxycodone, meaning the only difference between the 2 treatment arms occurs when the first treatment is administered. The innovative treatment is more effective and reduces the probability of AE but is more expensive.
The model uses a willingness-to-pay of £20 000, the threshold under which treatments are likely to receive a recommendation in the United Kingdom. 35 For a more in-depth presentation of all the model parameters, see Sullivan et al. 27 The PSA is based on gamma distributions for costs and beta distributions for probabilities and utilities. The parameters for these distributions are chosen such that the mean is informed by a literature review and the standard deviation is taken as 10% of the underlying mean estimate. For purely illustrative purposes, the per-person lifetime EVSI with a discount factor of 0.03 and a 15-year time horizon is compared with the trial costs to determine an optimal sample size.
Analysis for the Chronic Pain Example
A full VoI analysis, as set out by Tuffaha et al., 29 is undertaken for the chronic pain model. To begin, 100 000 simulations are taken from the prior for the model parameters. These are then fed through the Markov model to give 100 000 simulations for the incremental net benefit. Calculating the EVPPI 13, 14, 36 based on these simulations indicated that the most valuable parameters are those relating to the utility of the different health states for the first line of treatment. Specifically, the utility of not having any AE from the treatment and withdrawing from the treatment without experiencing AE.
In response to this, we designed an experiment to learn about the utility of these 2 health states, which, if known with certainty, would account for about 79% of the uncertainty in the decision. Questionnaires are a standard method for determining quality-adjusted lifeyears, and therefore we designed a trial in which questionnaires are sent to N participants. We assume, in a simplistic manner, that a participant is sent the questionnaire if they withdrew from the first treatment without any AE. They are then questioned about both health states, which they can accurately recall. This means that each questionnaire directly updates information about both these key utility parameters.
Responses from these questionnaires will be translated into a utility score for each health state. These utility scores are modeled as independent beta distributions with their means conditional on the utility of interest, the utility of not having AE and withdrawing without AE, and standard deviations equal to 0.3 and 0.31, respectively. 37 We consider sample sizes between N min = 10 and N max = 150. It is then assumed that only a proportion of the questionnaires are returned, leading to missingness in the data.
Within this context, 2 different designs are considered based on the results of a trial investigating whether financial incentives improve the rate of return of questionnaires in clinical trials 38 ; we assume that the questionnaire could be accompanied by a £5 incentive to complete. This incentive study demonstrated that sending the financial reward improved the response rate from 68.7% to 75.7% while increasing the cost from £4:64 to 9:35. The difference in cost is not equal to the incentive because nonrespondents are followed up by telephone, which costs staff time and other resources, and sending the reward reduces the number of follow-up calls needed. These costs are relatively low compared with standard trial costs but are used illustratively as they are comparable to the scale of the EVSI. Therefore, the EVSI will be used to answer 2 key questions regarding the design of this study; first, should the incentive be used? Second, how many questionnaires should be sent? The EVSI is estimated for both response rates using Q = 50 with 10 000 posterior simulations fed through the Markov model and used to estimate s 2 q for each q = 1, . . . , Q. The EVSI results using the momentmatching method are compared with nested Monte Carlo simulations for sample sizes 10, 25, 50, 100, and 150. These nested MC estimators were calculated using 100 000 realizations of the 2 utility scores to generate the future samples and then 100 000 posterior simulations per PSA simulation. Thus, 10 10 simulations were used for each sample size to estimate the EVSI using nested Monte Carlo simulations. This number of simulations was required to determine the EVSI to a sufficient degree of accuracy, whereas 500 000 simulations were sufficient for our novel method to estimate the EVSI across sample size. Figure 3 displays the net economic value for both designs; the gray curves are the economic value of the study with no incentive, and the black curves are the Figure 3 The economic value (difference between expected value of sample information [EVSI] and the cost of undertaking the study) of the 2 alternative questionnaire collection strategies for different sample sizes in the chronic pain example. The gray curves indicate the potential value of the study without incentives and the black curves the value of the study with incentives estimated using the momentmatching method. The black crosses represent the no-incentive Monte Carlo simulation estimates, and the gray crosses represent the same estimates for the incentive study. For larger sample sizes, the EVSI estimate is sufficiently certain that the 95% and 75% intervals are overlaid on the median. value of the incentive study from the moment-matching method. The economic value of a study is the difference between the EVSI and its cost 37 . Clearly, the no-incentive study is economically more valuable. This is because the reduced missingness in the questionnaire responses is not valuable enough to warrant the cost of the incentive. Note, however, that the dominance of the no-incentive study is uncertain for very small sample sizes as the EVSI ''distributions'' overlap. Figure 3 also shows the nested Monte Carlo estimates for the economic study value; the black crosses provide the value for the no-incentive study and the gray crosses for the incentive study. Using these estimates, we demonstrate that the moment-matching method with nonlinear regression is in line with the nested Monte Carlo simulation. This means that, in this example, our novel EVSI calculation method is accurate, despite the nonlinear and non-Gaussian model structure of the health economic model, and it significantly reduces the required number of simulations for this analysis.
Results for the Chronic Pain Model
Analyzing the economic value for different sample sizes determines that the optimal sample size in terms of economic benefit is 16 for the incentive study and 27 for the no-incentive study. Therefore, overall, the optimal study is a no-incentive study with 27 participants; the information gained from any additional patients is not worth the cost of sending the questionnaire and following up the nonrespondents. These sample sizes would change if more realistic assumptions were made about the trial costs and the total number of patients suffering from chronic pain was taken into account, but as an illustrative example, this highlights the potential outcomes from an EVSI analysis.
The total computational time to calculate the EVSI for both studies using our novel calculation method is 331 s or about 5½ min on a standard desktop computer with a Intel i7 Pro processor using R version 3.2.1. This includes fitting the regression model to calculate the EVSI across different sample sizes for both study designs, which is about 5 s per study. On the other hand, the nested Monte Carlo simulations required between between 7 and 68 days for each EVSI estimate, with a total computation time of about 311 days for all 10 estimates. This computational time could have been reduced by noting that the optimal sample size had been reached after 50 patients, but nonetheless, the computation time for the nested Monte Carlo method is in the order of days, if not months.
Discussion
The EVSI has frequently been touted as a method for study design, including determining the optimal study size. This can become computationally intensive, as the EVSI must be calculated separately for every sample size considered. In this article, therefore, we present an extension to the moment-matching method 23 that calculates the EVSI over different sample sizes with a minimal fixed additional computational cost. This is achieved by calculating the posterior variance of the incremental net benefit for about 50 different potential future samples with increasing sample sizes and then using nonlinear regression to estimate the expected posterior variance of the incremental net benefit for all sample sizes considered before calculating the EVSI using the moment-matching method. We demonstrate that this method is accurate using a real-life health economic model that evaluates interventions for the treatment of chronic pain. This implies that the EVSI could be used, within a realistic time frame, to compute an optimal sample size and be used alongside (and eventually instead of) standard frequentist sample size calculations.
Strengths and Limitations
This extension to the moment-matching method for EVSI calculation relies on finding the posterior distribution of the model parameters for about 50 future samples and then rerunning the health economic model for each of these posterior distributions. All other general purpose EVSI estimation methods seek to avoid rerunning the model and are therefore likely to require less computational effort to calculate the EVSI, especially in health economic models with a long runtime. However, the computational costs of these alternative methods will scale linearly with the number of sample sizes considered, making direct comparisons of computational time difficult to achieve. The accuracy of the moment-matching method is also higher when the data collection targets a high value set of parameters. This is highlighted in the supplementary material, in which higher value parameter subsets have smaller credible intervals for the EVSI.
The main advantage of the moment-matching method is that nested simulation imposes no restrictions on the complexity of the parameter distributions, the sampling distribution of the future data, or the economic model structure. Therefore, this EVSI calculation method can be used to design practical trials based on complex health economic models, which investigate a number of primary and secondary outcomes. Importantly, the generalizability of the moment-matching method has allowed for the development of an R package EVSI, 39 making this method relatively simple to implement. This R package has also extended this methodology to calculate the EVSI across different net benefit functions at a minimal extra cost and includes a suite of graphics to present EVSI results to key stakeholders. 40 Finally, this nonlinear regression method could be generalized further to estimate the EVSI across a number of different design decisions such as time horizon of the trial or the number of comparators. However, the functional form required to regress the posterior variance of the incremental net benefit to the time horizon of the trial may be more challenging to specify.
